Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis? Ana Martins; Sofia Pimenta; Daniela Oliveira; Rafaela Nicolau; Alexandra Bernardo; Teresa Martins Rocha; Lúcia Costa; Miguel Bernardes;

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;

Patient-reported outcomes in RA patients treated with tofacitinib or bDMARDs in real-life conditions in two Latin American countries J.M. Reyes; M.V. Gutierrez; H. Madariaga; W. Otero; R. Guzman; J. Izquierdo; M. Abello; P. Velez; D. Castillo; D. Ponce de Leon; T. Lukic; L. Amador;